Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Check Out Our Latest Analysis on Minerva Neurosciences

Minerva Neurosciences Stock Up 3.5 %

Minerva Neurosciences stock opened at $2.38 on Thursday. The business has a 50 day moving average price of $2.24 and a two-hundred day moving average price of $2.50. The stock has a market cap of $16.64 million, a price-to-earnings ratio of -5.41 and a beta of 0.12. Minerva Neurosciences has a 12 month low of $2.03 and a 12 month high of $13.49.

Minerva Neurosciences Company Profile

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Further Reading

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.